AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAY 9 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A detoxified J5 lipopolysaccharide (LPS)/group B meningococcal outer membrane protein complex vaccine induces significantly higher rates of survival in immunocompromised animals challenged with gram-positive organisms compared to unvaccinated animals, according to a recent report.
"In this study, active immunization was studied in neutropenic rats infected with Pseudomonas aeruginosa, in the presence or absence of ceftazidime therapy, and with Klebsiella pneumoniae," reported A.S. Cross and colleagues at the University of Maryland.
They found that this vaccine elicited a >200-fold increase in anti-J5 LPS antibody, which remained elevated throughout the duration of cyclophosphamide-induced neutropenia and for
Forty-eight percent of immunized rats survived after challenge with Pseudomonas versus 7% of control rats, while 65% of immunized rats survived Klebsiella challenge versus 13%, reported Cross et al.
In Pseudomonas-challenged rats that were treated with ceftazidime, the survival rates for immunized versus control rats were 61% and 0%, respectively ("Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis," Journal ...
Source: HighBeam Research, Vaccine Protects Immunocompromised Rats From Klebsiella, Pseudomonas...